Wang et al. reported that hsa-miR-183-5p was significantly upregulated in LUAD and hsa-miR-183-5p could promote lung carcinogenesis by directly targeting phosphatase tensin (PTEN), suggesting that hsa-miR-183-5p is a promising target in the diagnosis and treatment of lung cancer [83]. The gene discussed is PTEN; the disease is lung cancer.